UpGuard's Cyber Security Ratings range from 0 to 950. The higher the score, the more likely Exelixis is implementing good security practices.
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
This report shows a preliminary security rating for Exelixis. UpGuard scans billions of digital assets daily, in depth, across thousands of vectors. Data leak detection, vulnerability scanning and identity breach detection are just some of the advanced capabilities offered by the UpGuard platform.Get a deeper scan →
Read more about the latest issues in cybersecurity
Information Risk Management (IRM) is a form of risk mitigation through policies, procedures, and ...
Regulatory compliance monitoring is a key component of any cybersecurity program. But it's becoming ...
Compare Exelixis's security performance with other companies